CONTEXT: Attempts to determine the clinical significance of BRCA1/2 mutations in ovarian cancer have produced conflicting results. OBJECTIVE: To determine the relationships between BRCA1/2 deficiency (ie, mutation and promoter hypermethylation) and overall survival (OS), progression-free survival (PFS), chemotherapy response, and whole-exome mutation rate in ovarian cancer. DESIGN, SETTING, AND PATIENTS: Observational study of multidimensional genomics and clinical data on 316 high-grade serous ovarian cancer cases that were made public between 2009 and 2010 via The Cancer Genome Atlas project. MAIN OUTCOME MEASURES: OS and PFS rates (primary outcomes) and chemotherapy response (secondary outcome). RESULTS: BRCA2 mutations (29 cases) were associated with significantly better OS (adjusted hazard ratio [HR], 0.33; 95% CI, 0.16-0.69; P = .003 and 5-year OS, 61% for BRCA2-mutated vs 25% for BRCA wild-type cases) and PFS (adjusted HR, 0.40; 95% CI, 0.22-0.74; P = .004 and 3-year PFS, 44% for BRCA2-mutated vs 16% for BRCA wild-type cases), whereas neither BRCA1 mutations (37 cases) nor BRCA1 methylation (33 cases) was associated with prognosis. Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively). BRCA2-mutated, but not BRCA1-mutated cases, exhibited a "mutator phenotype" by containing significantly more mutations than BRCA wild-type cases across the whole exome (median mutation number per sample, 84 for BRCA2-mutated vs 52 for BRCA wild-type cases, false discovery rate <0.1). CONCLUSION: Among women with high-grade serous ovarian cancer, BRCA2 mutation, but not BRCA1 deficiency, was associated with improved survival, improved chemotherapy response, and genome instability compared with BRCA wild-type.
CONTEXT: Attempts to determine the clinical significance of BRCA1/2 mutations in ovarian cancer have produced conflicting results. OBJECTIVE: To determine the relationships between BRCA1/2 deficiency (ie, mutation and promoter hypermethylation) and overall survival (OS), progression-free survival (PFS), chemotherapy response, and whole-exome mutation rate in ovarian cancer. DESIGN, SETTING, AND PATIENTS: Observational study of multidimensional genomics and clinical data on 316 high-grade serous ovarian cancer cases that were made public between 2009 and 2010 via The Cancer Genome Atlas project. MAIN OUTCOME MEASURES: OS and PFS rates (primary outcomes) and chemotherapy response (secondary outcome). RESULTS:BRCA2 mutations (29 cases) were associated with significantly better OS (adjusted hazard ratio [HR], 0.33; 95% CI, 0.16-0.69; P = .003 and 5-year OS, 61% for BRCA2-mutated vs 25% for BRCA wild-type cases) and PFS (adjusted HR, 0.40; 95% CI, 0.22-0.74; P = .004 and 3-year PFS, 44% for BRCA2-mutated vs 16% for BRCA wild-type cases), whereas neither BRCA1 mutations (37 cases) nor BRCA1 methylation (33 cases) was associated with prognosis. Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively). BRCA2-mutated, but not BRCA1-mutated cases, exhibited a "mutator phenotype" by containing significantly more mutations than BRCA wild-type cases across the whole exome (median mutation number per sample, 84 for BRCA2-mutated vs 52 for BRCA wild-type cases, false discovery rate <0.1). CONCLUSION: Among women with high-grade serous ovarian cancer, BRCA2 mutation, but not BRCA1 deficiency, was associated with improved survival, improved chemotherapy response, and genome instability compared with BRCA wild-type.
Authors: Lea M Starita; Yuka Machida; Satish Sankaran; Joshua E Elias; Karen Griffin; Brian P Schlegel; Steven P Gygi; Jeffrey D Parvin Journal: Mol Cell Biol Date: 2004-10 Impact factor: 4.272
Authors: K J Patel; V P Yu; H Lee; A Corcoran; F C Thistlethwaite; M J Evans; W H Colledge; L S Friedman; B A Ponder; A R Venkitaraman Journal: Mol Cell Date: 1998-02 Impact factor: 17.970
Authors: S C Rubin; I Benjamin; K Behbakht; H Takahashi; M A Morgan; V A LiVolsi; A Berchuck; M G Muto; J E Garber; B L Weber; H T Lynch; J Boyd Journal: N Engl J Med Date: 1996-11-07 Impact factor: 91.245
Authors: H Aida; K Takakuwa; H Nagata; I Tsuneki; M Takano; S Tsuji; T Takahashi; T Sonoda; M Hatae; K Takahashi; K Hasegawa; H Mizunuma; N Toyoda; H Kamata; Y Torii; N Saito; K Tanaka; M Yakushiji; T Araki; K Tanaka Journal: Clin Cancer Res Date: 1998-01 Impact factor: 12.531
Authors: A Berchuck; K A Heron; M E Carney; J M Lancaster; E G Fraser; V L Vinson; A M Deffenbaugh; A Miron; J R Marks; P A Futreal; T S Frank Journal: Clin Cancer Res Date: 1998-10 Impact factor: 12.531
Authors: Kelly L Bolton; Georgia Chenevix-Trench; Cindy Goh; Siegal Sadetzki; Susan J Ramus; Beth Y Karlan; Diether Lambrechts; Evelyn Despierre; Daniel Barrowdale; Lesley McGuffog; Sue Healey; Douglas F Easton; Olga Sinilnikova; Javier Benítez; María J García; Susan Neuhausen; Mitchell H Gail; Patricia Hartge; Susan Peock; Debra Frost; D Gareth Evans; Rosalind Eeles; Andrew K Godwin; Mary B Daly; Ava Kwong; Edmond S K Ma; Conxi Lázaro; Ignacio Blanco; Marco Montagna; Emma D'Andrea; Maria Ornella Nicoletto; Sharon E Johnatty; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Ellen L Goode; Brooke L Fridley; Jennifer T Loud; Mark H Greene; Phuong L Mai; Angela Chetrit; Flora Lubin; Galit Hirsh-Yechezkel; Gord Glendon; Irene L Andrulis; Amanda E Toland; Leigha Senter; Martin E Gore; Charlie Gourley; Caroline O Michie; Honglin Song; Jonathan Tyrer; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Ulf Kristoffersson; Håkan Olsson; Åke Borg; Douglas A Levine; Linda Steele; Mary S Beattie; Salina Chan; Robert L Nussbaum; Kirsten B Moysich; Jenny Gross; Ilana Cass; Christine Walsh; Andrew J Li; Ronald Leuchter; Ora Gordon; Montserrat Garcia-Closas; Simon A Gayther; Stephen J Chanock; Antonis C Antoniou; Paul D P Pharoah Journal: JAMA Date: 2012-01-25 Impact factor: 56.272
Authors: Joyce Liu; Mihaela C Cristea; Paul Frankel; Susan L Neuhausen; Linda Steele; Verena Engelstaedter; Ursula Matulonis; Sharon Sand; Nadine Tung; Judy E Garber; Jeffrey N Weitzel Journal: Cancer Genet Date: 2012 Jan-Feb
Authors: Kathryn P Pennington; Tom Walsh; Maria I Harrell; Ming K Lee; Christopher C Pennil; Mara H Rendi; Anne Thornton; Barbara M Norquist; Silvia Casadei; Alexander S Nord; Kathy J Agnew; Colin C Pritchard; Sheena Scroggins; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher Journal: Clin Cancer Res Date: 2013-11-15 Impact factor: 12.531
Authors: John R McLaughlin; Barry Rosen; Joel Moody; Tuya Pal; Isabel Fan; Patricia A Shaw; Harvey A Risch; Thomas A Sellers; Ping Sun; Steven A Narod Journal: J Natl Cancer Inst Date: 2012-12-20 Impact factor: 13.506
Authors: Roel G W Verhaak; Pablo Tamayo; Ji-Yeon Yang; Diana Hubbard; Hailei Zhang; Chad J Creighton; Sian Fereday; Michael Lawrence; Scott L Carter; Craig H Mermel; Aleksandar D Kostic; Dariush Etemadmoghadam; Gordon Saksena; Kristian Cibulskis; Sekhar Duraisamy; Keren Levanon; Carrie Sougnez; Aviad Tsherniak; Sebastian Gomez; Robert Onofrio; Stacey Gabriel; Lynda Chin; Nianxiang Zhang; Paul T Spellman; Yiqun Zhang; Rehan Akbani; Katherine A Hoadley; Ari Kahn; Martin Köbel; David Huntsman; Robert A Soslow; Anna Defazio; Michael J Birrer; Joe W Gray; John N Weinstein; David D Bowtell; Ronny Drapkin; Jill P Mesirov; Gad Getz; Douglas A Levine; Matthew Meyerson Journal: J Clin Invest Date: 2012-12-21 Impact factor: 14.808
Authors: Robert E Bristow; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; William A Cliby Journal: J Natl Cancer Inst Date: 2013-03-28 Impact factor: 13.506